Key priorities should perhaps be nuclear receptor 4A1 (NR4A1) activators (Bridi et al., 2017) given that Nr4a1 down-regulation in isolates was greatest in terms of fold-change, and it was included in the 13% of DEGs shared with three of the four selected illnesses (namely schizophrenia, MDD and BP). The gene discussed is NR4A1; the disease is major depressive disorder.